Moderna's shares fell 2.5% before the bell on Friday, on concerns whether a new CDC advisory panel would back the use of the ...

The panel meeting for Moderna's RSV shot, scheduled for later this month, will be the "first time for investors to see the ...

The FDA expanded its approval of Moderna's RSV vaccine on Thursday to include adults under age 60 at increased risk of the ...

The Food and Drug Administration (FDA) expanded the approval of Moderna’s RSV vaccine late Thursday to include people 18 to ...

(Reuters) -Moderna's shares fell 2.5% before the bell on Friday, on concerns whether a new CDC advisory panel would back the use of the company's respiratory syncytial virus vaccine in a broader ...

With the U.S. FDA’s approval of Enflonsia (cesrovimab) to prevent respiratory syncytial virus (RSV) infection lower ...

The U.S. Food and Drug Administration on Thursday expanded the use of Moderna's respiratory syncytial virus vaccine to a ...

RSV infection typically leads to symptoms resembling ... ACIP’s members increases risk to all vaccine manufacturers. The CDC typically adopts ACIP recommendations and under the Affordable ...

As we continue to navigate the RSV season, ensuring that these products are widely available and administered in a timely manner will be key to protecting our youngest and most vulnerable populations.

RSV monoclonal antibody, clesrovimab,” which was approved by the FDA yesterday, Leerink Partners LLC analyst Daina Graybosch said. Insmed Inc.’s chair and CEO, Will Lewis, called the phase IIb trial ...

The CDC's Advisory Committee on Immunization Practices ... ages 50 to 59 be vaccinated for respiratory syncytial virus (RSV), and also added a new option for meningococcal vaccination.

or RSV, vaccines and meningococcal vaccines. The committee had voted on updated recommendations for those vaccines in April. Usually it is up to the CDC director to approve the recommendations.